Verrica Q1 2024: YCANTH revenue $3.2M, net loss $20.3M, cash runway into Q1 2025

Verrica Pharmaceuticals Inc.

2024-Q1 EPS reported -$0.44 revenue$3,826,000

YCANTH product revenue of $3.2M; no prior-year comparable as sales began Q3 2023.
Net loss $20.3M ($0.44/sh) vs $6.6M loss ($0.15/sh) in Q1 2023; non-GAAP loss $17.8M.
SG&A expense surged to $16.3M from $4.3M due to commercial ramp; R&D $4.9M vs $2.7M.
Cash and equivalents $48.9M; company expects to fund operations into Q1 2025.
Received NCE status (5-year exclusivity) and permanent J-Code for YCANTH; Phase 2 data for VP-315 (BCC) expected Q2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Verrica Pharmaceuticals Inc. reported first quarter ended March 31, 2024 results: revenue $3.2 million.

Period: first quarter ended March 31, 2024
Revenue: $3.2 million
Result: reported results

Exact text from the filing

Verrica recognized product revenue of $3.2 million in the first quarter of 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Verrica Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-136715

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.